The Filing Desk

Invivyd

IVVD · Nasdaq · Health Care · Financials, fiscal 2021 to 2025

IVVD · Last close · November 19, 2026
$0.45
Value Invivyd yourself

Invivyd's revenue rose 110.5% to $53 million in fiscal 2025. Its operating margin was −104.0%, up from −696.8% a year earlier. Free cash flow was −$58 million. The diluted share count rose 45.3%.

INVIVYD, INC. Latest fiscal year ended December 31, 2025 10-K filed March 5, 2026 · 0001193125-26-092547 Updated
Revenue
$53M
110.5%
Operating margin
−104.0%
592.8 pts
Net income
−$52M
 
Free cash flow
−$58M
 
Return on equity
−34.0%
104.8 pts
Market cap
$144M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Invivyd does

Invivyd is a biopharmaceutical company that develops monoclonal antibody medicines, which are lab-made proteins, to prevent and treat serious viral infections. It started with COVID-19 and says it aims to extend into other diseases such as respiratory syncytial virus and measles.

Its only authorized product is Pemgarda, which the FDA authorized for emergency use on March 22, 2024. It is given by intravenous infusion to prevent COVID-19 in adults and adolescents aged 12 and older who are moderately to severely immune compromised and unlikely to respond well to vaccination. It is an emergency use authorization rather than a full approval, and it lasts only while the COVID-19 emergency declaration for drugs stays in place and while the circulating variants are ones it is expected to work against.

Invivyd earns money by selling Pemgarda. It is also developing other antibody candidates, including VYD2311.

Its biggest risks, as it describes them

  • Its financial condition raises substantial doubt about whether it can continue as a going concern.
  • It depends heavily on Pemgarda, its only authorized product, which has only emergency use authorization.
  • New COVID-19 variants could reduce how well its antibodies work.
  • It has little experience selling products and has lost money since it began.
  • Its loan agreement has terms that, if broken, could lead to a default.
From Invivyd's annual report on Form 10-K, filed March 5, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Invivyd lost money in fiscal 2025: a net loss of $52 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments5429220169227
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage—————
Current ratio9.9x15.1x4.5x1.6x7.2x
Quick ratio9.9x15.1x4.5x1.2x7.1x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Invivyd's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Invivyd shares on the open market, and 4 insiders sold $341,120, all of it under trading plans set up in advance.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Aug 18, 2026Jill AndersenChief Legal Officer, SecretarySold plan30,706$0.84$25,793Form 4
Aug 18, 2026William E. DukeChief Financial OfficerSold plan18,425$0.84$15,477Form 4
Aug 18, 2026Robert D. Allen IIIChief Scientific OfficerSold plan17,043$0.84$14,316Form 4
Aug 17, 2026Jill AndersenChief Legal Officer, SecretarySold plan37,256$0.72$26,824Form 4
Aug 17, 2026William E. DukeChief Financial OfficerSold plan22,355$0.72$16,096Form 4
Aug 17, 2026Robert D. Allen IIIChief Scientific OfficerSold plan20,679$0.72$14,889Form 4
Feb 18, 2026Jill AndersenChief Legal Officer, SecretarySold plan34,939$1.58$55,204Form 4
Feb 18, 2026Timothy Edward LeeChief Commercial OfficerSold plan20,964$1.58$33,123Form 4
Feb 18, 2026Robert D. Allen IIIChief Scientific OfficerSold plan19,392$1.58$30,639Form 4
Feb 17, 2026Jill AndersenChief Legal Officer, SecretarySold plan32,771$1.54$50,467Form 4
Feb 17, 2026Timothy Edward LeeChief Commercial OfficerSold plan19,663$1.54$30,281Form 4
Feb 17, 2026Robert D. Allen IIIChief Scientific OfficerSold plan18,189$1.54$28,011Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40——1.4%
Altman Z''−8.05−28.78−0.36
Accruals ratio−8.3%0.3%2.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomePassFailFail
Debt fell relative to assets———
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assets—PassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Invivyd side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
InvivydFY25110.5%−104.0%−109.1%———
Q32 BioFY25—31.4%−62.4%—−2.8x3Compare
Protalix BioTherapeuticsFY25−1.2%−10.4%−25.8%———Compare
Gossamer BioFY25−57.7%−352.2%−353.5%——0Compare
Champions OncologyFY264.4%−1.9%−8.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

5 years of figures

Fiscal yearFY21FY22FY23FY24FY25
Income statement
Revenue——02553
Revenue growth————110.5%
Gross profit—————
Research and development18317915913738
Operating income−227−248−213−177−56
Net income−227−241−199−170−52
Diluted EPS (US$)−5.32−2.23−1.81−1.43−0.30
Diluted shares (millions)43108110119172
Cash flow
Cash from operations−185−220−173−170−58
Capital expenditure02100
Free cash flow−185−222−174−171−58
Dividends paid00000
Share buybacks00000
Acquisitions00000
Stock-based compensation1822192012
Balance sheet at fiscal year end
Cash and short-term investments5429220169227
Debt incl. finance leases—————
Total assets620383229130277
Total liabilities6227526235
Shareholders' equity55835617868242
Margins and ratios
Gross margin—————
Operating margin———−696.8%−104.0%
Net margin———−669.4%−98.2%
Free cash flow margin———−672.2%−109.1%
Rule of 40 (growth + FCF margin)————1.4%
Return on capital—————
Return on equity—−52.8%−74.5%−138.7%−34.0%
Return on assets—−48.1%−64.9%−94.8%−25.8%
Net debt to EBITDA—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Invivyd's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Invivyd.